1-3 of 3
Marie-Jose Claessen
Close
Sort by
Journal Articles

A Lysa Phase II Study of Oral JAK1/2 Inhibitor Ruxolitinib in Advanced Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL)

Eric W Van Den Neste, MD PhD, Marc Andre, MD, Thomas Gastinne, MD, Aspasia Stamatoullas, MD, Corinne Haioun, MD PhD, Amine Belhabri, MD, Oumedaly Reman, MD, Olivier Casasnovas, MD, Herve Ghesquieres, MD PhD, Gregor Verhoef, MD PhD, Marie-José Claessen, Hélène A Poirel, Marie-Christine Copin, Romain Dubois, Peter Vandenberghe, MD PhD, Ioanna-Andrea Stoian, Anne Ségolène Cottereau, MD, Laurent Knoops, MD PhD, Franck Morschhauser
Journal: Blood
Blood (2016) 128 (22): 4160.
https://doi.org/10.1182/blood.V128.22.4160.4160
Published: 2016
Journal Articles

Development of an Effective Safety Switch for Selective Elimination of Human T Cells In Vivo after Adoptive Transfer.

Tom van Meerten, BSc, Henk Rozemuller, PhD, Wendy J.M. Mackus, PhD, Paul W.H.I. Parren, PhD, Jan G.J. van de Winkel, PhD, Marie-Jose Claessen, MSc, Rozemarijn S. van Rijn, MD, Anton Hagenbeek, MD PhD, Anton C.M. Martens, PhD, Saskia B. Ebeling, PhD
Journal: Blood
Blood (2006) 108 (11): 5488.
https://doi.org/10.1182/blood.V108.11.5488.5488
Published: 2006
Journal Articles

High, Stable and Homogenous CD20 Expression for Efficient Rituximab-Induced Elimination of CD20+ Alloreactive Donor T Cells in the Novel CD20/Rituximab ‘Suicide’ System.

Tom van Meerten, Marie-Jose Claessen, Anton Hagenbeek, MD, Saskia Ebeling, PhD
Journal: Blood
Blood (2004) 104 (11): 1750.
https://doi.org/10.1182/blood.V104.11.1750.1750
Published: 2004